Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

Archive ouverte

Fernández de Larrea, Carlos | Kyle, Robert | Rosiñol, Laura | Paiva, Bruno | Engelhardt, Monika | Usmani, Saad | Caers, Jo | Gonsalves, Wilson | Schjesvold, Fredrik | Merlini, Giampaolo | Lentzch, Suzanne | Ocio, Enrique | Garderet, Laurent | Moreau, Philippe | Sonneveld, Pieter | Badros, Ashraf | Gahrton, Gösta | Goldschmidt, Hartmut | Tuchman, Sascha | Einsele, Hermann | Durie, Brian | Wirk, Baldeep | Musto, Pellegrino | Hayden, Patrick | Kaiser, Martin | Miguel, Jesús San | Bladé, Joan | Rajkumar, S. Vincent | Mateos, Maria Victoria

Edité par CCSD ; Nature Publishing Group -

International audience. Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.

Suggestions

Du même auteur

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective

Archive ouverte | Caers, Jo | CCSD

International audience. : Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder and bridges monoclonal gammopathy of undetermined significance to multiple myeloma (MM), based on higher lev...

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

Archive ouverte | Einsele, Hermann | CCSD

International audience

Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Archive ouverte | Termini, Rosalinda | CCSD

International audience. Abstract Purpose: Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (B...

Chargement des enrichissements...